Physician profile
Antonio Crespo
NPI 1033185392
$1,336.49
in general payments reported to CMS, 2019-2025
10 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $39.25 · 2021: $75.60 · 2022: $290 · 2023: $38.78 · 2024: $261 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.80 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $438.67 | 2022-2025 | Rebyota |
| Viiv Healthcare Company | $339.19 | 2019-2025 | Cabenuva |
| Astellas Pharma US INC | $161.99 | 2019 | |
| Gilead Sciences, INC. | $136.97 | 2019 | |
| Paratek Pharmaceuticals, INC. | $110.06 | 2022 | |
| Insmed, INC. | $80.21 | 2020-2023 | Arikayce |
| Tetraphase Pharmaceuticals, INC. | $23.23 | 2019 | |
| Dynavax Technologies Corporation | $17.41 | 2019 | |
| Angiodynamics, INC. | $17.17 | 2019 | |
| Osiris Therapeutics INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Crespo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.